Table 1 Basal clinical characteristics of the study population
GnRHa(107) | Control(204) | P | |
|---|---|---|---|
Age(years) | 22.86 ± 6.59 | 23.49 ± 6.85 | 0.435 |
Diagnosis for HSCT | |||
Lymphoblastic leukemia | 32(29.91) | 87(42.65) | 0.001 |
Myeloid leukemia | 32(29.91) | 77(37.75) | |
Aplastic anemia | 28(26.17) | 17(8.33) | |
Myelodysplastic syndrome | 13(12.15) | 19(9.31) | |
Others | 2(1.87) | 4(1.96) | |
Conventional chemotherapy prior to the myeloablative regimen for HSCT | |||
Yes | 69(64.49) | 170(83.33) | < 0.001 |
No | 38(35.51) | 34(16.67) | |
TBI exposure | |||
Yes | 2(1.87) | 8(3.92) | 0.330 |
No | 105(98.13) | 196(96.08) | |
Alkylator agent exposure | 107(100.00) | 204(100.00) | / |
Pre-transplantation FSH(mIU/ml) | 8.86 ± 5.27 | 9.31 ± 4.60 | 0.338 |
Pre-transplantation LH(mIU/ml) | 8.39 ± 6.13 | 7.45 ± 3.35 | 0.403 |
Pre-transplantation E2(pg/ml) | 82.27 ± 60.43 | 78.90 ± 37.08 | 0.614 |